Full text
PDFPage 745
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Hamblin T. J. Clinical parameters for evaluating biological response modifier therapy. Eur J Cancer Clin Oncol. 1989;25 (Suppl 3):S7–S9. [PubMed] [Google Scholar]
- Hamblin T. J. Interleukin 2. BMJ. 1990 Feb 3;300(6720):275–276. doi: 10.1136/bmj.300.6720.275. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rosenberg S. A., Lotze M. T., Muul L. M., Chang A. E., Avis F. P., Leitman S., Linehan W. M., Robertson C. N., Lee R. E., Rubin J. T. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987 Apr 9;316(15):889–897. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]
- Rosenberg S. A., Packard B. S., Aebersold P. M., Solomon D., Topalian S. L., Toy S. T., Simon P., Lotze M. T., Yang J. C., Seipp C. A. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988 Dec 22;319(25):1676–1680. doi: 10.1056/NEJM198812223192527. [DOI] [PubMed] [Google Scholar]
- Walewski J., Paietta E., Dutcher J., Wiernik P. H. Evaluation of natural killer and lymphokine-activated killer (LAK) cell activity in vivo in patients treated with high-dose interleukin-2 and adoptive transfer of autologous LAK cells. J Cancer Res Clin Oncol. 1989;115(2):170–174. doi: 10.1007/BF00397919. [DOI] [PMC free article] [PubMed] [Google Scholar]
- West W. H., Tauer K. W., Yannelli J. R., Marshall G. D., Orr D. W., Thurman G. B., Oldham R. K. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med. 1987 Apr 9;316(15):898–905. doi: 10.1056/NEJM198704093161502. [DOI] [PubMed] [Google Scholar]